Recent Updates
Recently added Catalysts
CRIS Neutral Sentiment

TakeAim Lymphoma Clinical Outcomes Bermuda Hematology 2024 Presentation

Friday, August 16, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: Curis Inc. is set to present clinical outcomes from the TakeAim Lymphoma study at the Bermuda Hematology 2024 conference. The presentation will cover various aspects of the ongoing studies related to lymphoma and leukemia, including pipeline updates on their investigational drugs. Details regarding the company's collaborations and patient resources are also highlighted.
Price reaction · baseline $84.8 (2024-08-15 close) · hit pre-market · clean, no other CRIS news in the window
day 0 close · peak
-1.4%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~1 mo
High dilution risk
Lead asset
Emavusertib
Phase 2 · Chronic Lymphocytic Leukemia

Full Press Release Details

• About Company Overview Management Board of Directors Advisory Boards
• Collaborations Partner Collaborations Scientific & Research Collaborations
• Patients Patients Overview Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL Understanding Primary CNS Lymphoma Compassionate Use Policy
• Pipeline Pipeline Overview Emavusertib (CA-4948) Fimepinostat CA-170 CA-327
• Scientific Resources
• Investors Overview Press Releases Events and Presentations Corporate Governance Committee Composition Contact the Board Financial Information SEC Filings Annual Reports IRS Form 8937 Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage Contact Us
• Careers Life at Curis Open Positions Benefits
• Contact
• Company Overview
• Management
• Board of Directors
• Advisory Boards
• Partner Collaborations
• Scientific & Research Collaborations
• Patients Overview
• Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• Understanding Primary CNS Lymphoma
• Compassionate Use Policy
• Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• TakeAim Lymphoma
• TakeAim Leukemia
• TakeAim CLL
• Pipeline Overview
• Emavusertib (CA-4948)
• Fimepinostat
• CA-170
• CA-327
• Overview
• Press Releases
• Events and Presentations
• Corporate Governance Committee Composition Contact the Board
• Financial Information SEC Filings Annual Reports IRS Form 8937
• Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage
• Contact Us
• Committee Composition
• Contact the Board
• SEC Filings
• Annual Reports
• IRS Form 8937
• Interactive Chart
• Historical Stock Lookup
• Analyst Coverage
• Life at Curis
• Open Positions
• Benefits

Frequently Asked Questions

What is the TakeAim Lymphoma study?

The TakeAim Lymphoma study focuses on investigating treatments for lymphoma and is part of Curis's ongoing clinical research.

When will the Bermuda Hematology 2024 presentation occur?

Curis will present the TakeAim Lymphoma clinical outcomes at the Bermuda Hematology 2024 conference.

What drugs are included in Curis's pipeline?

Curis's pipeline includes investigational drugs like Emavusertib, Fimepinostat, CA-170, and CA-327.

What collaborations does Curis have?

Curis engages in various partner collaborations and scientific research collaborations to advance its studies.

ShareAdd on Google
Tags: CRIS Viatris Investor Conferences Healthcare Curis TakeAim Lymphoma clinical outcomes Bermuda Hematology 2024 pipeline updates
Last updated: Aug 16, 2024

Biotech snapshot

Cash runway
$5M liquidity · $3M/mo burn
~1 mo
High dilution risk
Lead asset
EmavusertibPhase 2
Chronic Lymphocytic Leukemia →